Another phase II study showed that GPC3-positive HCC patients treated with GPC3-derived peptide vaccine as an adjuvant therapy had a significantly lower recurrence rate after one year than patients who received surgery alone (24% vs. 48%, p = 0.047) (107). This evidence concerns the gene GPC3 and hepatocellular carcinoma.